Tag Archives: NASDAQ:BNGO

Oppenheimer Issues a Buy Rating on BioNano Genomics (BNGO)

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to BioNano Genomics (BNGO – Research Report) today and set a price target of $15.00. The company’s shares closed last Tuesday at $8.37. According to TipRanks.com, DeGeeter is a top 100 analyst

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (NASDAQ: BNGO) and Moderna (NASDAQ: MRNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics (BNGO – Research Report) and Moderna (MRNA – Research Report) with bullish sentiments. BioNano Genomics (BNGO) In a report released

BioNano Genomics (BNGO) Receives a New Rating from a Top Analyst

In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to BioNano Genomics (BNGO – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $0.93, close to its 52-week low

BioNano Genomics (BNGO) Received its Third Buy in a Row

After Oppenheimer and Roth Capital gave BioNano Genomics (NASDAQ: BNGO) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy assigned a Buy rating to BioNano Genomics yesterday and set a price

Oppenheimer Thinks BioNano Genomics’ Stock is Going to Recover

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $1.50. The company’s shares closed last Thursday at $0.51, close to its 52-week low of

Maxim Group Thinks BioNano Genomics’ Stock is Going to Recover

Maxim Group analyst Jason McCarthy assigned a Buy rating to BioNano Genomics (BNGO – Research Report) today and set a price target of $3.00. The company’s shares closed last Wednesday at $0.40, close to its 52-week low of $0.39. According